Download Free Medical Endometriosis PowerPoint Presentation

Endometriosis PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Endometriosis, which is titled "Endometriosis", to know about the presence of endometrial tissue (glands & stroma) outside the uterus which induces chronic inflammatory reaction.

Tags : Endometriosis, endometrial tissue, glands, stroma, uterus, chronic inflammatory reaction

Published on : Jul 28, 2021 | Views : 5422 | Downloads : 50

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Endometriosis Presence of endometrial tissue (glands & stroma) outside the uterus which induces chronic inflammatory reaction Affects general physical, mental & social well being. Endometriosis
Slide 2-

Presence of endometrial tissue (glands & stroma) outside the uterus ___________________________________________________ It is a progressive debilitating disease affecting general physical, mental & social well being of women ___________________________________________________ Affects nearly 7 to10% of the women in reproductive age, 30% of those who are infertile or present with pain. ___________________________________________________ The most frequent sites of implantation are pelvic viscera and the peritoneum ___________________________________________________ Less commonly cervix, hernial sacs, the umbilicus, laparotomy or episiotomy scars may be involved
Slide 3-

ppt slide no 3 content not found
Slide 4-

Sites of endometriosis Pelvic Ovary Cul de sac Uterosacrals Posterior surface of uterus Posterior broad ligament Rectovaginal septum Tubes and round ligaments Extrapelvic sites Intestines (rectosigmoid, cecum, terminal ileum, proximal colon, appendix) Lungs & thorax Urinary tract Less common sites Cervix Hernial sacs Umblicus Laparotomy/episiotomy sites Tubal stumps after sterilization Rarest Extremities
Slide 5-

Why Newer Concepts are required First described by Daniel Shroen in 1690 but still we are not very sure of its definitive cause Endometriosis is considered to be an enigmatic disease owing to Lack of specific symptoms, Poorly understood pathogenesis Limited effective therapeutic options The last three decades have witnessed a significant volume of research related to endometriosis Incidence is increasing b/c of changing life style, increased awareness and better diagnostic modalities
Slide 6-

Endometriotic lesions Variable appearance Peritoneum Typical Superficial Early red lesions Powder burn or gunshot Black, dark brown or bluish puckered lesions White plaques Adhesions –flimsy,vascular,dense (DIE) Deeply Infiltrating Endometriosis , >5mm depth Atypical or subtle lesions Serous / clear vesicle Yellowish discoloration Ovaries Superficial Subovarian adhesions Endometriomas
Slide 7-

ppt slide no 7 content not found
Slide 8-

ppt slide no 8 content not found
Slide 9-

Why does it occur ? Transplantation theory (Sampson) Coelomic metaplasia theory(Mayer and Ivanoff) Induction theory (Merril) Genetic factors Immunologic factors The cellular and molecular etiologic theories label endometriosis as an inflammatory and estrogen dependent disorder
Slide 10-

Transplantation theory: Originally proposed by Sampson in 1920 Based on assumption that endometriosis is caused by implantation of the endometrial cells by transtubal regurgitation during menstruation. Seen in 70-90% of women , more common in endometriosis
Slide 11-

A; androstendione, AA; arachidonic acid, Arom; aromatase P450,E2; estradiol, IL-I β interleukin1 β, TNF- tumor necrosis factor , VEGF; vascular endothelial growth factor Peritoneal Environment in Endometriosis
Slide 12-

ppt slide no 12 content not found
Slide 13-

ppt slide no 13 content not found
Slide 14-

Is It Inherited ? No Mendelian pattern of inheritance, multi factorial inheritance is suggested. Risk of endometriosis is 7 times if first degree relative is affected. 75% incidence in monozygotic twins. No mutations have been identified so far. Aneuploidy- chromosome 11,16,17, losses of 1p,22q,5p,6q,16,&18 have been demonstrated in endometriotic cells.
Slide 15-

Grading of Endometriosis
Slide 16-

ppt slide no 16 content not found
Slide 17-

ppt slide no 17 content not found
Slide 18-

Clinical Presentation Severe dysmenorrhoea Deep dyspareunia Chronic pelvic pain Ovulation pain Perimenstural pain/bleed Infertility Chronic fatigue Pain during defecation Variable Need high index of suspicion Usually delay of many years b/w Symptoms and Definitive diagnosis
Slide 19-

Dysmenorrhea & pelvic pain- Often starts after years of pain free menses. Starts before the onset of periods and continues throughout menses Most studies failed to show correlation between degree of pain and severity of endometriosis. Causation of pain – local peritoneal inflammation, deep infiltration- proximity to nerve fibers, adhesion formation and fibrotic thickening, collection of shed menstrual blood in implants, resulting in painful traction with physiological movements.
Slide 20-

Infertility Possible mechanisms Mechanical causes Altered tubo ovarian relationships Altered tubal motility Impaired oocyte pickup Alterations in peritoneal fluid ↑Macrophages, PGs, Cytokines - affect sperm motility, sperm oocyte interaction, sperm phagocytosis, implantation failure Alteration of systemic immune response ↑ antiendometrial antibodies –(Gajbhiye et al 2008,Mathur et al 2000) ↑ cell mediated gametocyte injury
Slide 21-

Hormonal factors- Defective folliculogenesis Luteinized unruptured follicle (4-35%) Luteal phase deficiency Hyperprolactinemia and galactorrhea Fertilization and implantation failure Monthly fecundity rate is lower in women with mild disease ( 5-11% vs 25%) No evidence that spontaneous abortion rates are higher in endometriosis.
Slide 22-

.Diagnosis Pelvic tenderness, a fixed retroverted uterus, tender utero-sacral ligaments or enlarged ovaries suggest endometriosis. Deeply infiltrating nodules on utero-sacral ligaments/POD or visible lesions on vagina or cervix give more certainty. The detection is improved if examined during menstruation. Acceptance may be an issue Rectovaginal examination is required if suspecting DIE.
Slide 23-

Diagnosis For a definitive diagnosis of endometriosis visual inspection of the pelvis at laparoscopy is the gold standard investigation, unless disease is visible in the vagina or elsewhere.(RCOG recommendation level B) There is insufficient evidence to justify timing the laparoscopy at a specific time in the menstrual cycle but it should not be performed during or within 3 months of hormonal treatment so as to avoid under diagnosis .
Slide 24-

Is Histological confirmation necessary ? (RCOG Recommendations) Positive histology confirms the diagnosis of endometriosis Negative histology does not exclude it. Whether histology should be obtained if peritoneal disease alone is present is controversial. Visual inspection is usually adequate but histological confirmation of at least one lesion is ideal. In case of ovarian endometrioma (more than 3cm) and in deeply infiltrating disease histology should be obtained to identify endometriosis and to exclude rare instances of malignancy.
Slide 25-

TVS in diagnosing Endometriosis Compared to laparoscopy, TVS has limited value in diagnosing peritoneal endometriosis But it is a useful tool both to make and exclude the diagnosis of ovarian endometrioma. (RCOG level A ,Recomendations.) TVS may have a role in the diagnosis of disease involving the bladder or rectum Sensitivity-83% & specificity-98% for endometrioma.
Slide 26-

Classical appearance- homogenous, hypoechoic mass with low levels internal echoes with hyperechoic foci within wall. 95% show internal echoes & hyperechoic lesions are due to cholesterol deposits. Lesions- unilocular/ moltilocular with thick/thin septa
Slide 27-

Differential diagnosis: Dermoid cyst- acoustic shadowing (calcium) & echogenic lesion (fat). Hemorrhagic cyst- high levels of internal echoes with thin walled cyst, resolves with time. Cystic neoplasm Transrectal ultrasound: Better resolution, diagnostic accuracy, restricted field of visualization (Distal bowel can be imaged). Deposits- round hypoechoic, infilteration of bowel wall is seen as thickening of muscularis propria. Sensitivity-97%, specificity-89% for rectal lesions ( better than MRI).
Slide 28-

Role of Doppler Diagnostic accuracy is enhanced by doppler. Pericystic flow with RI more than 0.45, indicating low resistance waveform. MRI: Advantage of imaging entire pelvis in multiple planes. Particularly useful in evaluating rectum & cul de sac. Appearance depends upon- iron content, proteins and products of blood degradation.
Slide 29-

CA -125 Low sensitivity (25-50%), not used as screening method. Helpful to predict recurrence. Levels in non menstrual phase- Minimal/mild-14-31U/ml Moderate/severe-13-95U/ml 80% of patients with pelvic pain & raised CA125 levels have endometriosis, while only 6% of those without endometriosis have raised CA125 levels. (Pittaway et al 1989) High levels of CA-125 have been reported in cases of large endometrioma/ ruptured endometriomas. (Shiau et al 2008,Kahraman et al 2007,Ghaemmaghami et al 2007,Phuphong et al 2004)
Slide 30-

Laparoscopy – gold standard Diagnose the extent and severity of disease. Should not be performed within 3 months of hormonal therapy to avoid under diagnosis. Methodical approach required. Thoroughly inspect the lateral sidewalls, all ovarian surfaces, both sides of broad ligament, bladder, bowel serosa and inferior aspects of the cul de sac. Uterine manipulation helps in visualizing POD and recto vaginal septum Photography and video recording of the findings should be done ideally.
Slide 31-

Treatment Options Medical Therapy NSAIDs and Cox2 inhibitors COCs Progestogens Anti progestins GnRH agonists and antagonists Aromatase inhibitors Selective Estrogen Receptor Modulators Selective Progesteron Receptor Modulators Surgical Treatment Conservative Surgery Definitive Surgery
Slide 32-

Green-top Guideline No. 24 October 2006 (Minor revisions October 2008) Inconclusive evidence, if NSAIDs (specifically naproxen ) are effective in managing end. associated pain.(level-A) Suppression of ovarian function for 6 mths reduces end. associated pain.(level-A) COCs, MPA, Danazol, Gestrinone and GnRH agonists are equally effective but their adverse effects and cost profiles differ and can be chosen accordingly (level-B)
Slide 33-

ACOG recommends 3 months trial of NSAID & cyclic OCP. If pain persists after 3 months then laparoscopy If patient > 18 yrs and wish to avoid surgery-empiric GnRHagonists If pain resolves then diagnosis of endometriosis is confirmed Any low dose OCP containing 30-35 mg of ethinyl estradiol used continuously (to achieve amenorrhea) can be effective in treatment of endometriosis. (Moghessi et al 1999) Cyclic OCP is used to provide prophylaxis against either the development or recurrence of endometriosis. Nuva ring can also be used.
Slide 34-

Progesterones(cont)
Slide 35-

GnRH Agonist Causes pseudomenopause by down regulation of pitutary, very effective Indicated if patient is unable to have an acceptable degree of pain control with COCs. Not to be given if< 17 yrs (ESHRE 2005) Leuprolide 3.75mg/mth, Gosereline 3.6mg/mth Buserelin, Nafarelin,Triporelin Add back therapy CEE .625 mg+ norethindrone , noreth. alone or tibolone 2.5 mg + 1200 mg of Calcium & Vitamin D daily Goal of add back – effectively treat endometriosis associated pain while preventing vasomotor symptoms or bone loss. Treatment up to 2 yrs with COC add back appears to be effective and safe in terms of pain relief and bone density. GnRH Antagonists
Slide 36-

LNG Intra Uterine System LNG- IUS appears to reduce endometriosis associated pain (RCOG level -A) Insertion after laparoscopic surgery for endometriosis associated pain, significant reduction in the risk of recurrent moderate–severe dysmenorrhoea at 1 year follow-up.(level A) Causes significant reduction in pain, dysmenorrhea, dyspareunia and size of rectovaginal endometriosis (upto 3yrs). It also has minimal systemic effects, effective contraception & long term 5 years of benefit, as compared to 6 mths, typical of GnRHa treatment. Dienogest ; highly selective PRM, as effective as GnRHa May prove better option,Now available…2mg continuously
Slide 37-

Danazol 400-800 mg/day, first drug approved for end. in US. Adverse side effects limit its use Gestrinone Causes cellular inactivation and degeneration of endometrial implants. 1.25- 2.5mg twice weekly for 24weeks. Amenorrhea occurs in 50-100% of cases. Equally effective, Seems to prove good alternative Side effects- androgenic but less intense than danazol. Pregnancy is contraindicated due to masculinization of fetus. Mifepristone 25-50mg/day,Seems promising
Slide 38-

Aromatase inhibitors- Aromatase is the key enzyme responsible for estrogen production in the ectopic endometrium, further stimulated by PGE2. Inhibitors decrease local estrogen synthesis and inhibit the growth of endometriotic implants. Require add-back therapy to protect bones. letrozole ,2.5mg along with norethisterone 2.5mg/ calcium(1000mg)+vit D (800IU) for 6 months reduced pelvic pain scores and no significant change in BMD (Ailawadi et al 2004,Remorgida et al 2007) Preliminary data favours its (letrazole, anastrazole ) potential future use .But RCTs are needed to confirm.
Slide 39-

SERMs(Selective Estrogen Receptor Modulators ) Non-steroidal anti-estrogens bind to ERs, can act as either estrogen agonists or antagonists, depending on the target tissue. Have estrogen antagonist activity on the endometrium but agonist activity on bone and circulating lipoproteins. Role yet to be studied in humans. TZE-5323, raloxifene- decrease volume of implants in dose dependent manner in animal studies.
Slide 40-

Selective Progestrone Receptor Modulators SPERMs Can act as either agonists or antagonists of progestogenic activity, depending on the target tissue. Suppress endometrial proliferation selectively in the presence of an estrogenic environment, allowing the treatment of endometriotic implants without the side effects of systemic estrogen deprivation. Role yet to studied in humans. J867, J956, J912 and J1042 being studied.
Slide 41-

Endometriosis and Fertility Hormonal or antihormonal therapy has no beneficial effect on fertility either alone or as an adjunct to surgery ( RCOG recommendation) only surgical ablation or excision of disease will restore fertility ( RCOG recommendation)
Slide 42-

Infertility and endometriosis Suppression of ovarian function to improve fertility in minimal–mild endometriosis is not effective and should not be offered for this indication alone. There is no evidence of its effectiveness in more severe disease. (level A RCOG) Postoperative hormonal treatment has no beneficial effect on pregnancy rates after surgery. (level A RCOG)
Slide 43-

Infertility and endometriosis Ablation of endometriotic lesions plus adhesiolysis to improve fertility in minimal–mild endometriosis is effective (level A,RCOG). The role of surgery in improving pregnancy rates for moderate-severe disease is uncertain. No randomised controlled trials or meta-analyses are available to answer the question.
Slide 44-

Conservative Surgery An asymptomatic patient with incidental finding of Endometriosis does not require any treatment Excision or ablation reduces pain. Excision rather than drainage or fulguration provides better pain relief, reduced recurrence, and histological diagnosis Surgical excision with scissors, bipolar coagulation or laser Ovarian endometrioma < 4 cms – Aspirated, irrigated and interior wall vaporized to destroy mucosal lining >4cm cystectomy is recommended (level–A RCOG)
Slide 45-

Infertility and endometriosis Laparoscopic ovarian cystectomy is recommended if an ovarian endometriomas ≥ 4 cm in diameter to confirm the diagnosis histologically improve access to follicles possibly improve ovarian response prevent endometriosis progression The woman should be counseled regarding the risks of reduced ovarian function after surgery.
Slide 46-

IUI improves fertility in patients when combined with ovarian stimulation. Pregnancy rate is lower in than with unexplained fertility. Poor ovarian response and need for high dose of gonadotropin therapy for ovarian stimulation. IVF is appropriate treatment, especially if tubal function is compromised, if there is also male factor infertility, and/or other treatments have failed. Treatment with a GnRH agonist for 3–6 months before IVF in women with endometriosis increases the rate of clinical pregnancy.(level A)
Slide 47-

Recurrent endometriosis Spontaneous resolution occurs in about 20% of endometriosis stage I-II. Residual disease- persistence of symptoms or reappearance of symptoms within 3 months . Recurrence usually appears after 3 months . Incidence-6-30% in various studies. Depends on- age, stage of disease, prior treatment, completeness of surgery, extent of peritoneal disease. Usually presents as chronic pelvic pain , dysmenorrhea
Slide 48-

Recurrent endometriosis Diagnosis- rising CA-125,TVS, MRI, laparoscopy. Treatment- Pain killers Hormones- progesterones, OCPs, GnRH analogues Conservative surgery- Indicated if medical therapy fails or contraindicated or intolerable side effects. Cystectomy/ adhesiolysis may be an option after IVF fails.. Postoperative hormone therapy delays recurrence but does not reduce the recurrence. LNG IUCD- reduces recurrences post surgery & role is being studied in recurrent disease. Hysterectomy with bilateral salphigo oophorectomy
Slide 49-

Angiogenesis Inhibitors Antioxidants-Vitamin C,Vitamin E Tumor Necrosis Factors- inhibitors Matrix Metalloproteinase Inhibitors Immunomodulators Chinese methods Green Tea Stem Cells Therapy Gene therapy Newer Treatments
Slide 50-

Pentoxiphylline could change the immune cell function by inhibition of Cytokine and TNF-alpha secretion. (Cochrane review 2009) VEGF- C suggested to be an effective factor for significant reduction in endometriotic implants after Pentoxiphylline administration (Vlahos et al. 2010) Another immunomodulator Etanercept (ETA) has promising reductive effect equal to Letrazol in early investigation (Ceyhan et al. 2011)
Slide 51-

According to Cochrane review Chinese herbal medicine has shown equal results as compared to Gestrinone (Flower et al. 2009) Abdominal acupuncture showed significant effect in dysmenorrhoea relief and decreasing CA 125 levels (Xiang et al. 2011)
Slide 52-

Surgery for pain relief Drug therapy may relieve inflammation and reduce pain in early superficial disease but corrective surgery +/- drug therapy is preferable (Padwick 1999) Rectovaginal, rectal and uterosacral lesions always need surgery Endometriomas always need surgery Abnormal Anatomy and adhesions always need surgery
Slide 53-

Role of surgery in pain Ablation of endometriotic lesions reduces endometriosis-associated pain, outcome is poorest in minimal endometriosis. (level A,RCOG) There is no evidence that laparoscopic uterine nerve ablation(LUNA) is necessary when ablating endometriotic lesions and LUNA by itself has no effect on dysmenorrhoea associated with endometriosis. (level A,RCOG) There is currently no evidence to recommend the use of LUNA to treat endometriosis although there is some evidence for the use of presacral neurectomy (PSN). (Cochrane data 2005)
Slide 54-

Postoperative hormonal treatment does not produce a significant reduction in pain recurrence at 12 or 24 months and has no effect on disease recurrence. (level A,RCOG) LNG-IUS, inserted after laparoscopic surgery for endometriosis associated pain, significantly reduced the risk of recurrent moderate–severe dysmenorrhoea at 1 year follow-up. (level A,RCOG)
Slide 55-

Deep Infiltrating Endometriosis
Slide 56-

Definitive Surgery ? Ovarian conservation In DIE & severe cases hysterectomy and removal of all visible endometriotic tissue can be done. BSO may result in improved pain relief & reduced chances of future surgery .(RCOG guidelines) In cases with normal ovaries, hysterectomy with ovarian conservation and removal of endometriotic lesions should be considered.(ACOG guidelines 2010) TAH-BSO is reserved for women with debilitating symptoms ,who have completed childbearing & other therapies have failed. (ASRM &Canada OBG Society,2010)
Slide 57-

Conclusions